Lode Debrabandere, Ph.D., President and Chief Executive Officer, joined Osiris in July 2006. Prior to joining Osiris, Dr. Debrabandere served for over four years with Bristol-Myers Squibb as Vice President of Strategic Marketing for Neuroscience and Infectious Diseases. He led the Neuroscience Unit and was the Global Brand Leader for Abilify™. Previously, Dr. Debrabandere led the Marketing department of UCB Pharma Inc., focusing in the areas of allergy/respiratory (Zyrtec™) and neurology (Keppra™). Dr. Debrabandere earned an MBA, a Ph.D. in pharmaceutical sciences, toxicology, and a Pharm. D. degree, all from the University of Leuven, Belgium.
Philip R. Jacoby, Jr., Chief Financial Officer and Corporate Secretary, joined Osiris in April 2005. Mr. Jacoby previously served as the Company’s Controller and Chief Accounting Officer. From 1999 to 2004, Mr. Jacoby served as Vice President and Corporate Controller for FTI Consulting, Inc., a global business financial and economic consulting firm. Mr. Jacoby began his career with Arthur Andersen & Co., and earned his undergraduate degree in business and public administration from the University of Maryland.
Michelle LeRoux Williams, Ph.D., Chief Scientific Officer, joined Osiris in October 2001. Previously at Osiris, Dr. Williams served as Director of Orthopedics. In that role Dr. Williams was responsible for the development of Osteocel from initial concept through market launch. In 2005, Osteocel became the world’s first commercially available stem cell product. Additionally, Dr. Williams advanced the Chondrogen program from preclinical testing through human clinical evaluation. Prior to joining Osiris, Dr. Williams completed an NIH postdoctoral fellowship in tissue engineering at Columbia University, evaluating cellular constructs for the repair and regeneration of cartilage in arthritis patients. Dr. Williams earned a bachelor's degree in mechanical engineering from Rice University and a Ph.D. in biomedical engineering from Duke University.
Frank D. Czworka, Jr., Vice President and General Manager of Wound Care, joined Osiris in August 2011. Mr. Czworka has over 20 years of sales and marketing experience in the Life Science industry with a demonstrated track record of building specialty sales forces and developing product access in managed markets, including public and private payer accounts. Prior to Osiris, he served as Vice President of Sales at MedImmune, responsible for leading a 450 person sales team for Synagis®, a $1B monoclonal antibody for RSV and FluMist®, the first intranasal influenza vaccine. He also led sales efforts at other biotech organizations including TAP Pharmaceuticals and Auxilium Pharmaceuticals. Mr. Czworka holds a bachelor's degree in Marketing from the University of Central Florida.
Douglas Jacobstein, M.D., Senior Medial Director, joined Osiris in February 2009. Dr. Jacobstein has served as Medical Director in gastroenterology at UCB, Inc. and was Director of Clinical Development and Medical Affairs at Alba Therapeutics. Prior to joining industry, Dr. Jacobstein was a practicing pediatric gastroenterologist with clinical and research interests in the use of disease modifying biologics for inflammatory diseases of the gastrointestinal tract. Dr. Jacobstein is certified by the American Board of Pediatrics in Pediatric Gastroenterology. He completed his fellowship in gastroenterology at the Children’s Hospital of Philadelphia (CHOP) and residency at St. Christopher’s Hospital for Children. Dr. Jacobstein earned his Bachelor’s degree from Cornell University and his medical degree from the University of Maryland.